Literature DB >> 8661410

Antigenic variation of SIV: mutations in V4 alter the neutralization profile.

N E Kinsey1, M G Anderson, T J Unangst, S V Joag, O Narayan, M C Zink, J E Clements.   

Abstract

Antigenic variation is a characteristic feature of lentiviral infection. The SIV/macaque model of AIDS provides an ideal system in which to investigate the molecular basis of antigenic variation. The purpose of this study was to genetically map the nucleotide changes in env that alter the neutralization phenotype of SIV. Serum taken from an SIVmac239-infected macaque (2D) at 30 weeks postinoculation was found to neutralize the input virus (SIVmac239) and an isolate, P9, obtained at 10 weeks p.i., but did not neutralize two other isolates, P13 and P23, obtained at 20 and 52 weeks, respectively. Sequence analysis of these virus variants revealed clustered amino acid changes in V1 and single base pair changes in V2-V4 of P13 and P23. Infectious recombinant viruses in which the V1 and V1-V3 sequences of SIVmac239 were replaced with those of P13 or P23 retained the neutralization profile of SIVmac239; both were neutralized by macaque 2D serum. Recombinants containing the entire surface glycoprotein (gp120) (V1-V5) and the 5' portion of gp41 of P13 and P23 and those containing gp120 sequences from V4 through the 5' portion of the transmembrane glycoprotein (gp41) were not neutralized by 2D serum. Using a panel of monoclonal antibodies in radioimmunoprecipitation assays, P23 and recombinants containing V4 and V5 of P23 were shown to be antigenically distinct from P13 and SIVmac239. The majority of the amino acid changes in the antigenically distinct viruses were clustered in V4 (amino acids 413-418) and these changes created new potential N-linked glycosylation sites. This study demonstrates that a small number of specific amino acid changes (amino acids 412 to 418 in the env gene) in the V4 region of the SIV envelope glycoprotein can alter antibody recognition and neutralization and that these phenotypic changes may be associated with altered glycosylation of the envelope.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8661410     DOI: 10.1006/viro.1996.0348

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  31 in total

1.  Characterization of a macaque recombinant monoclonal antibody that binds to a CD4-induced epitope and neutralizes simian immunodeficiency virus.

Authors:  J Glamann; V M Hirsch
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

2.  Simian immunodeficiency virus envelope compartmentalizes in brain regions independent of neuropathology.

Authors:  Maria F Chen; Susan Westmoreland; Elena V Ryzhova; Julio Martín-García; Samantha S Soldan; Andrew Lackner; Francisco González-Scarano
Journal:  J Neurovirol       Date:  2006-04       Impact factor: 2.643

3.  Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies.

Authors:  B Chackerian; L M Rudensey; J Overbaugh
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys.

Authors:  Wendy W Yeh; Laura M Brassard; Caroline A Miller; Aravind Basavapathruni; Jinrong Zhang; Srinivas S Rao; Gary J Nabel; John R Mascola; Norman L Letvin; Michael S Seaman
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

5.  The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection.

Authors:  Penny L Moore; Elin S Gray; Isaac A Choge; Nthabeleng Ranchobe; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

6.  Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1.

Authors:  Rong Rong; S Gnanakaran; Julie M Decker; Frederic Bibollet-Ruche; Jesse Taylor; Jeffrey N Sfakianos; John L Mokili; Mark Muldoon; Joseph Mulenga; Susan Allen; Beatrice H Hahn; George M Shaw; Jerry L Blackwell; Bette T Korber; Eric Hunter; Cynthia A Derdeyn
Journal:  J Virol       Date:  2007-03-14       Impact factor: 5.103

7.  Infectivity and neutralization of simian immunodeficiency virus with FLAG epitope insertion in gp120 variable loops.

Authors:  Melissa E Laird; Ronald C Desrosiers
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

8.  Potent antibody-mediated neutralization and evolution of antigenic escape variants of simian immunodeficiency virus strain SIVmac239 in vivo.

Authors:  Shuji Sato; Eloisa Yuste; William A Lauer; Eun Hyuk Chang; Jennifer S Morgan; Jacqueline G Bixby; Jeffrey D Lifson; Ronald C Desrosiers; Welkin E Johnson
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

9.  Envelope vaccination shapes viral envelope evolution following simian immunodeficiency virus infection in rhesus monkeys.

Authors:  Aravind Basavapathruni; Wendy W Yeh; Rory T Coffey; James B Whitney; Peter T Hraber; Ayush Giri; Bette T Korber; Srinivas S Rao; Gary J Nabel; John R Mascola; Michael S Seaman; Norman L Letvin
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

10.  Envelope variation as a primary determinant of lentiviral vaccine efficacy.

Authors:  Jodi K Craigo; Baoshan Zhang; Shannon Barnes; Tara L Tagmyer; Sheila J Cook; Charles J Issel; Ronald C Montelaro
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.